Noteworthy

Jun 12, 2017
Pharmaceutical Executive
An honoree at HBA’s recent Women of the Year awards luncheon, Bahija Jallal’s story is one of courage and resilience.
Jun 11, 2017
Jackie DeAngelis outlines three common mistakes that hinder access attainment when launching a new drug.
Jun 10, 2017
Pharma has long recognized the power of key opinion leaders, but with HCPs and patients now acquiring much of their information online, there is a new opportunity for "digital opinion influencers".
Jun 09, 2017
As digital technologies transform drug development and marketing, a retooled medical affairs function can be a competitive differentiator, write Loic Plantevin, Christoph Schlegel and Maria Gordian.
Jun 08, 2017
Pharmaceutical Executive
Pharma leaders go on the defensive over drug pricing regulations, while experts slam the politicization of healthcare, writes Pharm Exec's Michelle Maskaly.
Jun 08, 2017
Pharmaceutical Executive
By Pharmaceutical Executive Editors
In its 11th annual feature, Pharm Exec breaks from the norm to instead profile five products that are currently shining the spotlight on critical and highly debated aspects of healthcare and R&D.
Jun 06, 2017
At recent the BETHEEXPERT 2017 event in Budapest, we asked Romuald Braun what pharma should be focusing on with regard to its labeling activities.
Jun 02, 2017
With the UK's General Election set for June 8, Leela Barham looks what the competing parties are promising for pharma and healthcare
May 31, 2017
Companies developing potential master brands need to work earlier in the clinical development program to ensure reliable diagnostics will be available to all potential patients, writes Barri Blauvelt.
May 23, 2017
CBER is gearing up to facilitate the development and approval of regenerative medicine advanced therapies, as defined by the 21st Century Cures Act.
native1_300x100
lorem ipsum